Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

NCT00261612 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Mantle-Cell

Interventions

DRUG: bortezomib
DRUG: rituximab
DRUG: dexamethasone
PROCEDURE: treatment protocol

Sponsor

Medical University of Vienna